Why This Matters
For the first time in Medicare's history, eligible beneficiaries can access GLP-1 weight-loss drugs through the federal program that insures more than 67 million Americans. The Medicare GLP-1 Bridge Program launched July 1, 2026, charging eligible Part D enrollees a flat $50 per month co-pay for certain GLP-1 medications prescribed for obesity.